Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_assertion description "[We conducted a clinical trial of low-dose decitabine plus aclacinomycin/cytarabine (AA) treatment (DAA) for 20 patients with refractory/relapsed de novo acute myeloid leukemia (AML) or AML transformed from myelodysplastic syndrome (MDS/AML) in order to examine its efficacy and tolerability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_assertion evidence source_evidence_literature NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_assertion SIO_000772 22895556 NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_assertion wasDerivedFrom befree-20150227 NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_assertion wasGeneratedBy ECO_0000203 NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP781437.RAErXsF-bZPZ7eVJ-4wGtDmRBl_hKA7rDbi8Rb6-CPgbU130_provenance.